{"id":38785,"date":"2026-06-16T11:05:00","date_gmt":"2026-06-16T15:05:00","guid":{"rendered":"https:\/\/www.drugpatentwatch.com\/blog\/?p=38785"},"modified":"2026-05-09T15:47:19","modified_gmt":"2026-05-09T19:47:19","slug":"the-patent-dance-playbook-winning-bpcia-litigation-strategy-for-biologics-and-biosimilar-applicants","status":"publish","type":"post","link":"https:\/\/www.drugpatentwatch.com\/blog\/the-patent-dance-playbook-winning-bpcia-litigation-strategy-for-biologics-and-biosimilar-applicants\/","title":{"rendered":"The Patent Dance Playbook: Winning BPCIA Litigation Strategy for Biologics and Biosimilar Applicants"},"content":{"rendered":"\n
\"\"<\/figure>\n\n\n\n

Biologic drugs represent 2% of all U.S. prescriptions but consume 37% of net drug spending. [1] That arithmetic explains everything about why the Biologics Price Competition and Innovation Act (BPCIA) and its pre-litigation information exchange \u2014 the so-called “patent dance” \u2014 is the most consequential procedural framework in pharmaceutical law today.<\/p>\n\n\n\n

A single strategic decision made in the first weeks after an abbreviated Biologics License Application (aBLA) is filed can shift billions of dollars in revenue. Do you engage in the dance or opt out? Which patents do you list? When do you send the notice of commercial marketing? Get these calls wrong and you lose years of market exclusivity or face an injunction on the eve of launch.<\/p>\n\n\n\n

This guide is for the people making those calls: patent counsel at biosimilar developers, IP strategists at reference product sponsors (RPS), and the business executives who fund them. It explains the mechanics of the BPCIA framework, how the law actually plays out in litigation, and what the most successful players have done to win \u2014 or at least survive.<\/p>\n\n\n\n

\n\n\n\n

Part I: Why the Stakes Are What They Are<\/strong><\/h2>\n\n\n\n

The Numbers Behind the Dance<\/strong><\/h3>\n\n\n\n

The global biosimilar market was estimated at roughly $39.6 billion in 2025 and is projected to reach $151.6 billion by 2033, growing at an 18.4% compound annual rate. [2] In the United States alone, biosimilars and generics collectively saved the healthcare system $467 billion in 2024. [3] Biosimilar competition supported an estimated 460 million incremental days of patient therapy that would not have occurred at reference product prices. [4]<\/p>\n\n\n\n

That is the public health story. The competitive story is different. For a biosimilar developer who has spent between $100 million and $250 million over seven to eight years to bring a product through clinical development, a single court ruling extending a competitor’s market exclusivity by six months can obliterate a return on investment. For a reference product sponsor defending a $15 billion annual revenue drug, every month of exclusivity is worth over a billion dollars.<\/p>\n\n\n\n

The BPCIA determines which company collects that money.<\/p>\n\n\n\n

\n

“Molecules currently facing biosimilar competition total $38 billion of invoice spending, while a further $96 billion is the target of biosimilars in development or approved but not yet launched.” \u2014 IQVIA Institute, Biosimilars in the United States 2023\u20132027<\/em> [5]<\/p>\n<\/blockquote>\n\n\n\n

The biologics market also now comprises 46% of total U.S. medicine spending by invoice price. [5] This is the economic backdrop for every procedural decision in a BPCIA case. When patent attorneys argue over whether a step in the dance was properly completed, they are arguing over drug revenue at a scale that would have seemed fantastical two decades ago.<\/p>\n\n\n\n

What the BPCIA Created and Why It Matters<\/strong><\/h3>\n\n\n\n

Congress enacted the BPCIA as part of the Affordable Care Act on March 23, 2010. The law created an abbreviated licensure pathway for biosimilar products through the FDA, analogous to the Hatch-Waxman pathway for small-molecule generics. [6] It also created the patent dance: a mandatory-in-design but optional-in-practice information exchange between a biosimilar applicant and the reference product sponsor designed to identify and resolve patent disputes before a biosimilar hits the market.<\/p>\n\n\n\n

The policy logic is sound. Rather than have biosimilar companies launch and immediately face infringement suits \u2014 or have reference product sponsors file suit without knowing which manufacturing processes a biosimilar uses \u2014 the BPCIA attempted to create a structured pre-litigation process. Both sides would share information, negotiate which patents to litigate in a first wave, and ideally resolve disputes before patients and payers are caught in the crossfire.<\/p>\n\n\n\n

In practice, the dance has become a strategic weapon for both sides \u2014 and understanding how to wield it requires understanding every step.<\/p>\n\n\n\n

\n\n\n\n

Part II: The Mechanics of the Patent Dance<\/strong><\/h2>\n\n\n\n

Step One: The aBLA Submission and the Clock Starts<\/strong><\/h3>\n\n\n\n

The patent dance begins the moment a biosimilar applicant submits an aBLA to the FDA. Under 42 U.S.C. \u00a7 262(l)(2)(A), the applicant “shall provide” the reference product sponsor with a copy of the aBLA and detailed information describing the manufacturing processes for the proposed biosimilar. This must happen within 20 days of the FDA notifying the applicant that its application has been accepted for review.<\/p>\n\n\n\n

This is where the first major strategic decision arises: whether to provide the aBLA at all. The Supreme Court’s 2017 ruling in Sandoz v. Amgen<\/em> held that this initial disclosure is optional under federal law. [7] An applicant can simply refuse to hand over the aBLA. The RPS’s only federal remedy is to file a patent infringement lawsuit \u2014 it cannot obtain an injunction under federal law to compel disclosure. That ruling fundamentally changed how biosimilar applicants think about entry strategy.<\/p>\n\n\n\n

Step Two: The RPS’s Patent List (the “3A List”)<\/strong><\/h3>\n\n\n\n

If the applicant does provide the aBLA, the RPS has 60 days to respond with a list of patents it believes could reasonably be asserted if the applicant were to make, use, sell, or offer for sale the biosimilar product. This is commonly called the “3A list” after its statutory reference. The RPS must list every patent it believes is relevant \u2014 including patents it does not intend to immediately sue on. This list is consequential because it defines the universe of patents available for Phase II litigation later.<\/p>\n\n\n\n

The strategic calculus for the RPS at this step is uncomfortable. Listing too few patents looks weak. Listing every conceivable patent \u2014 a tactic AbbVie demonstrated with Humira’s 61-patent lists against individual biosimilar challengers \u2014 is aggressive but resource-intensive for both parties. [8] It also opens those patents up to scrutiny; once listed, they can be challenged at the Patent Trial and Appeal Board (PTAB) through Inter Partes Review (IPR) by the applicant or by any interested third party.<\/p>\n\n\n\n

Step Three: The Applicant’s Patent List (the “3B List”)<\/strong><\/h3>\n\n\n\n

Within 60 days of receiving the RPS’s 3A list, the biosimilar applicant must provide its own list of patents it believes could be asserted, along with a detailed statement of the basis for the applicant’s belief that each listed patent is invalid, unenforceable, or will not be infringed by the biosimilar product. Alternatively, the applicant can state that it will not challenge the patent’s validity.<\/p>\n\n\n\n

This “3B list” and accompanying claim charts are among the most sensitive documents in the entire litigation. The applicant is essentially writing its own invalidity and non-infringement arguments before any lawsuit is filed. These documents later become central exhibits in litigation. Patent counsel spend enormous resources getting these positions right because they will be tested in court.<\/p>\n\n\n\n

Step Four: The RPS’s Response and Reciprocal Statements<\/strong><\/h3>\n\n\n\n

The RPS then has 60 days to respond to the applicant’s 3B statements \u2014 providing its own claim charts on infringement and its responses to the applicant’s invalidity arguments. At this point, both parties have exchanged detailed legal positions on every patent in the 3A list. The information exchange is complete.<\/p>\n\n\n\n

Step Five: Negotiating the Phase I Patent List<\/strong><\/h3>\n\n\n\n

After exchanging claim charts, the parties have 15 days to negotiate which patents will be included in the first wave of litigation (Phase I). If they cannot agree, the applicant selects the patents for Phase I litigation. This is a structural advantage for biosimilar applicants \u2014 they get to pick which patents they fight first, allowing them to select patents they believe are weakest or most vulnerable to invalidity arguments.<\/p>\n\n\n\n

Once the Phase I list is set, the RPS has 30 days to file suit. If no suit is filed within that window, the applicant may immediately bring a declaratory judgment action on the listed patents.<\/p>\n\n\n\n

From FDA acceptance of the aBLA to Phase I litigation being filed, the full dance takes approximately 245 days when all steps take their allotted time. [9] This is not a trivial delay \u2014 it is eight months of pre-launch maneuvering before a single brief is filed in federal court.<\/p>\n\n\n\n

Step Six: Phase II \u2014 The Notice of Commercial Marketing and the Preliminary Injunction Window<\/strong><\/h3>\n\n\n\n

Phase II begins when the biosimilar applicant provides the RPS with notice of intended commercial marketing, which must be given at least 180 days before the first commercial sale. [10] Upon receiving this notice, the RPS may seek a preliminary injunction to prevent the biosimilar from launching while the Phase II patents are litigated.<\/p>\n\n\n\n

The Supreme Court’s ruling in Sandoz v. Amgen<\/em> clarified a critical question about timing: applicants may provide the 180-day notice before FDA approval. [7] This means a company that filed its aBLA can send the notice of commercial marketing while the application is still under FDA review, potentially compressing the total pre-launch waiting period. Before that ruling, the conventional interpretation was that the notice could only be given post-approval \u2014 effectively adding six more months of delay.<\/p>\n\n\n\n

Phase II covers all patents that appeared on the 3A and 3B lists but were not litigated in Phase I. There is no further information exchange requirement \u2014 the positions are already established. This is where, as one analysis puts it, “all hell can break loose.” [11] If the 3A list included 60 patents and only 10 were litigated in Phase I, the RPS can assert the remaining 50 in Phase II. The applicant faces this with no additional procedural shields.<\/p>\n\n\n\n

\n\n\n\n

Part III: The Decision to Dance \u2014 Or Not<\/strong><\/h2>\n\n\n\n

The Opt-Out Calculus After Sandoz v. Amgen<\/strong><\/h3>\n\n\n\n

The Supreme Court’s June 2017 ruling in Sandoz v. Amgen<\/em> was the first time the Court addressed the BPCIA, and it reshaped how every subsequent biosimilar applicant thought about the dance. [7] Sandoz had opted out entirely for its filgrastim biosimilar Zarxio, telling Amgen it would not share the aBLA or manufacturing information and advising Amgen of its right to sue.<\/p>\n\n\n\n

The Court held that this opt-out was legally permissible under federal law. An RPS cannot use federal law to compel an applicant to participate in the dance. The opt-out is a legitimate strategic choice. [7]<\/p>\n\n\n\n

Many in the industry predicted this ruling would gut the dance \u2014 why would any applicant voluntarily provide detailed manufacturing information to a competitor if they did not have to? Three years later, the practical effect was more muted than anticipated. Cases filed after June 2017 actually saw a slight uptick in overall compliance with the patent dance. [12] Why?<\/p>\n\n\n\n

Because opting out has real costs. An applicant who skips the dance loses the structural advantage of selecting Phase I patents. When an applicant refuses to share the aBLA, the RPS \u2014 facing no pre-litigation framework \u2014 can file suit asserting every patent in its portfolio simultaneously. The applicant then bears the cost of litigating all patents at once, with no strategic filter applied. For a reference product sponsor with a large patent estate, this effectively means the biosimilar applicant trades the dance’s complexity for potentially worse litigation exposure.<\/p>\n\n\n\n

The choice between participating and opting out ultimately depends on the size of the RPS’s patent portfolio, the applicant’s assessment of which patents are strongest, and the applicant’s financial resources for parallel litigation tracks. A well-resourced biosimilar developer facing a modest patent estate might benefit from opting out. A smaller developer facing a 100-patent thicket probably needs the dance’s sorting mechanism.<\/p>\n\n\n\n

Why Reference Product Sponsors Sometimes Prefer an Opt-Out<\/strong><\/h3>\n\n\n\n

Counterintuitively, there are scenarios where an RPS prefers it when the applicant opts out. If the RPS has a very strong composition-of-matter patent it is confident is valid and infringed, it may prefer to litigate that single patent immediately in federal court rather than spend eight months exchanging claim charts on dozens of weaker patents it might not want exposed to scrutiny.<\/p>\n\n\n\n

The dance also forces the RPS to articulate its patent positions in writing before litigation begins. For a reference product sponsor with patents it knows are vulnerable, detailed claim charts in the 3B exchange can be damaging. An applicant who opts out denies the RPS this forced disclosure \u2014 but also denies itself the structural benefit of controlling Phase I patent selection.<\/p>\n\n\n\n

\n\n\n\n

Part IV: The AbbVie Humira Blueprint \u2014 How Patent Thickets Weaponize the Dance<\/strong><\/h2>\n\n\n\n

The Architecture of a Patent Thicket<\/strong><\/h3>\n\n\n\n

No case study in the history of biologic IP strategy has been more consequential \u2014 or more controversial \u2014 than AbbVie’s defense of Humira (adalimumab). AbbVie shielded Humira from biosimilar competition for 21 years through a portfolio of at least 105 patents, and in some analyses as many as 136. [13] The drug generated over $20 billion in annual revenue at its peak. [14]<\/p>\n\n\n\n

The patents were not primarily new inventions. An independent analysis concluded that approximately 80% of Humira’s U.S. patent portfolio covered incremental modifications \u2014 different formulations, new methods of manufacturing, and method-of-use patents for conditions Humira was already widely known to treat. [15] The citrate-free, high-concentration formulation that AbbVie introduced was a notable example: by shifting the market to a new patented formulation that reduced injection-site pain, AbbVie forced biosimilar developers who had designed their products to match the original formulation into a difficult choice \u2014 launch an “inferior” product or redesign. [16]<\/p>\n\n\n\n

The legal structure enabling this was the BPCIA’s absence of a statutory cap on patents that can be asserted. Unlike the Hatch-Waxman framework for small molecules, the BPCIA places no limit on how many patents an RPS can list. [17] In practice, this meant AbbVie included 61 patents on its 3A list against Amgen’s Amjevita biosimilar alone. [8] With five major biosimilar challengers, the total scope of patent assertion was staggering.<\/p>\n\n\n\n

The Settlement Architecture: Trading Delay for Certainty<\/strong><\/h3>\n\n\n\n

AbbVie’s endgame was not to win every lawsuit. It was to create sufficient litigation uncertainty that biosimilar developers would accept settlement terms requiring delayed U.S. launch. AbbVie reached settlements with nine biosimilar manufacturers, allowing a 2023 U.S. market entry \u2014 well after initial patent expirations but 11 years ahead of the furthest-reaching patent’s 2034 expiry. [18] The settlements also required biosimilar developers to pay royalties to AbbVie on future U.S. sales. [19]<\/p>\n\n\n\n

The settlement-as-strategy model has proven durable. Approximately 67% of terminated BPCIA litigations have ended in settlements or stipulated voluntary dismissals rather than full judicial resolution. [20] For both sides, settlement offers certainty: the biosimilar applicant gets a definite launch date, and the RPS gets royalty income and a managed competitive entry rather than an unpredictable court ruling.<\/p>\n\n\n\n

Former FDA Commissioner Scott Gottlieb characterized patent thickets around reference biologics as “purely designed to deter the entry of approved biosimilars.” [20] That assessment may be accurate as a matter of policy, but it does not change the legal reality that the strategy worked. Humira’s biosimilar entry in Europe happened years before the U.S. \u2014 a direct consequence of the American patent system’s permissive treatment of pharmaceutical secondary patents combined with the BPCIA’s unlimited assertion framework.<\/p>\n\n\n\n

The ETHIC Act and Legislative Pushback<\/strong><\/h3>\n\n\n\n

Congress has not ignored the Humira playbook. The Eliminating Thickets to Increase Competition (ETHIC) Act proposes to limit a patent holder to litigating just one patent from each family of obvious variants. [14] The logic is that terminal disclaimers \u2014 the legal mechanism that allows continuation patents on obvious variations of the same invention \u2014 have been weaponized to create artificial density in patent portfolios. AbbVie’s Humira portfolio included 105 patents connected by 436 terminal disclaimers. [16]<\/p>\n\n\n\n

Whether the ETHIC Act passes in its current form is uncertain. But the legislative attention signals that the era of uncapped multi-patent assertion under the BPCIA may be entering a period of constraint. Reference product sponsors building their next-generation patent thickets should plan for the possibility that assertion volume will face statutory limits.<\/p>\n\n\n\n

\n\n\n\n

Part V: PTAB \u2014 The Parallel Battlefield<\/strong><\/h2>\n\n\n\n

Why Biosimilar Applicants Fight on Two Fronts<\/strong><\/h3>\n\n\n\n

The BPCIA patent dance and district court litigation are not the only arenas where these patent disputes are fought. The Patent Trial and Appeal Board (PTAB), created by the America Invents Act of 2011, offers biosimilar applicants a faster, cheaper, and often more favorable venue for challenging the validity of RPS patents. [21]<\/p>\n\n\n\n

PTAB proceedings operate on a preponderance-of-evidence standard \u2014 lower than the clear-and-convincing evidence required to invalidate patents in district court. PTAB’s administrative patent judges are technically specialized. And IPR proceedings typically conclude within 18 to 24 months of filing a petition. [22] Compare that to patent litigation in federal court, which routinely takes four to six years from filing to trial.<\/p>\n\n\n\n

For biosimilar applicants facing a large patent thicket, PTAB creates what litigation strategists call a “pincer movement”: the applicant engages the RPS in the patent dance while simultaneously filing IPR petitions against the most threatening patents in the thicket. [23] A PTAB victory that invalidates a patent removes it from the chessboard entirely \u2014 before it can be fully litigated in federal court.<\/p>\n\n\n\n

The Statistical Case for PTAB Challenges<\/strong><\/h3>\n\n\n\n

The numbers support PTAB as a challenger’s forum. In Fiscal Year 2024, bio\/pharma petitions demonstrated an institution rate of 73%, compared to the overall IPR institution rate of 68%. [24] Challengers who successfully obtained institution then found that the board invalidated at least one patent claim in a substantial fraction of bio\/pharma proceedings. One analysis found challengers were successful in invalidating at least one claim in 70% of all instituted IPRs against biologic patents. [21]<\/p>\n\n\n\n

The Federal Circuit has affirmed PTAB decisions at a rate consistently between 70% and 80% since 2015, with reversals or vacaturs occurring in fewer than 23% of appealed cases through 2023. [24] That means a PTAB win is durable in most cases \u2014 not easily reversed on appeal.<\/p>\n\n\n\n

The 2025 PTAB Reforms and the New Landscape<\/strong><\/h3>\n\n\n\n

The strategic environment at PTAB shifted materially in 2025. USPTO Director Coke Morgan Squires implemented procedural reforms centralizing institution decisions under direct oversight, proposing rules addressing serial petitions, and tightening real-party-in-interest disclosure requirements. [25]<\/p>\n\n\n\n

The immediate effect was dramatic: overall IPR institution rates collapsed to below 45% under the new discretionary denial policies. But \u2014 and this is the critical nuance \u2014 bio\/pharma patents were being instituted at or near 100% even as overall rates fell. [26] The reforms appear to be throttling access for other technology sectors while leaving pharmaceutical patent challenges largely intact.<\/p>\n\n\n\n

The reform environment also prompted a shift toward alternative challenge mechanisms. Ex parte reexamination offers an efficient, lower-risk option when double-patenting-based challenges are viable. [25] Post-Grant Review (PGR), available only within nine months of patent grant, has broader challenge grounds than IPR and is emerging as a primary tool for attacking newly issued secondary patents before they can become entrenched in a thicket.<\/p>\n\n\n\n

Biosimilar applicants monitoring a reference product’s patent prosecution should now file PGR petitions within the nine-month window as a standard practice \u2014 not an afterthought. The opportunity to challenge on the broadest possible grounds closes quickly.<\/p>\n\n\n\n

The PREVAIL Act Threat<\/strong><\/h3>\n\n\n\n

The Protecting and Restoring Our Intellectual Property (PREVAIL) Act, if enacted, would raise the IPR burden of proof to clear and convincing evidence, impose standing requirements limiting who can petition, and restrict multiple petitions against the same patent. [27] This would substantially reduce PTAB’s value as a challenger tool and shift the balance back toward reference product sponsors.<\/p>\n\n\n\n

Generic industry groups and patient advocacy organizations argue that PTAB is functioning as intended \u2014 clearing out low-quality secondary patents that the USPTO issued in error. The legislative outcome remains uncertain, but biosimilar developers should model their IP strategy under both the current framework and a post-PREVAIL scenario. The tool you rely on today may look very different in three years.<\/p>\n\n\n\n

\n\n\n\n

Part VI: Phase I Litigation \u2014 The First Wave<\/strong><\/h2>\n\n\n\n

Selecting Battlefield Patents<\/strong><\/h3>\n\n\n\n

When Phase I litigation begins, the applicant’s ability to select which patents are litigated in the first wave is the dance’s most powerful structural feature for biosimilar developers. The rational selection strategy is to choose patents that are most amenable to invalidity arguments \u2014 patents with extensive prior art, narrow claims, or formulation patents that can be designed around.<\/p>\n\n\n\n

What the applicant wants to avoid is being forced to litigate composition-of-matter patents on the reference biologic’s core active ingredient in Phase I. These patents are typically the hardest to invalidate and the most likely to support injunctions. By selecting weaker peripheral patents for Phase I, the applicant can potentially dispose of them quickly while building arguments for the Phase II battle over the core portfolio.<\/p>\n\n\n\n

Reference product sponsors understand this dynamic. Their counter-strategy involves making the 3A list so large and the strongest patents so numerous that the applicant cannot isolate them from the Phase I selection without also selecting patents that will create adverse precedent. AbbVie’s 61-patent 3A list against Amgen’s biosimilar was not accidental \u2014 it was designed to make any selection strategy by Amgen complicated and costly.<\/p>\n\n\n\n

The 30-Day Filing Window and the Preliminary Injunction Dynamic<\/strong><\/h3>\n\n\n\n

Once Phase I patents are identified, the RPS has 30 days to file suit. This creates a “forced hand” dynamic that prevents the RPS from indefinitely delaying litigation. [10] If the RPS does not file within 30 days, the applicant can bring a declaratory judgment action. Either way, the clock to resolution begins.<\/p>\n\n\n\n

The preliminary injunction question is often the central strategic fight in Phase I. If the RPS can obtain a preliminary injunction preventing biosimilar launch pending resolution of the Phase I patents, it effectively wins delay equivalent to the litigation timeline \u2014 often two to four years in federal district court. The legal standard for a preliminary injunction requires the RPS to show likelihood of success on the merits, irreparable harm, that the balance of hardships favors an injunction, and that the public interest does not disfavor one.<\/p>\n\n\n\n

In March 2025, the Federal Circuit affirmed a preliminary injunction preventing Celltrion from launching its aflibercept biosimilar after Regeneron successfully demonstrated likelihood of success on its ‘865 patent. [28] That decision illustrates that courts remain willing to grant these injunctions when the underlying patent appears strong \u2014 which reinforces the reference product sponsor’s incentive to identify and preserve at least one unassailable patent for Phase I.<\/p>\n\n\n\n

Celltrion, Janssen, and the Consequence of Partial Compliance<\/strong><\/h3>\n\n\n\n

Early BPCIA litigation produced instructive cases on what happens when the dance is followed imperfectly. In Janssen’s litigation against Celltrion over an infliximab biosimilar, Janssen asserted that Celltrion had not provided complete manufacturing information as required by the BPCIA. Janssen sued for infringement of six patents, seeking to enforce compliance with the dance’s information-exchange steps. [29] Four of the six patents were ultimately dismissed, but the remaining patent issues proceeded \u2014 illustrating that partial compliance creates legal exposure without delivering the strategic benefits of full compliance.<\/p>\n\n\n\n

The lesson is binary: either engage the dance fully and extract its benefits, or opt out entirely and live with the consequences of litigation without the framework’s protections. Partial compliance creates a worst-case scenario.<\/p>\n\n\n\n

\n\n\n\n

Part VII: Phase II Litigation \u2014 Where the Real War Begins<\/strong><\/h2>\n\n\n\n

The Compressed Timeline Problem<\/strong><\/h3>\n\n\n\n

After Sandoz v. Amgen<\/em>, biosimilar applicants can send the 180-day notice of commercial marketing before FDA approval. This has caused Phase I and Phase II litigation timelines to compress \u2014 in many cases, both phases are effectively running simultaneously. [7] Reference product sponsors who had previously expected a clear sequential structure now face the need to prepare Phase II litigation even before Phase I is resolved.<\/p>\n\n\n\n

For biosimilar applicants, this means the Phase II patent list \u2014 all patents in the 3A and 3B exchanges not litigated in Phase I \u2014 needs to be assessed and strategized from day one, not treated as a future problem. Companies that treat Phase II as something to worry about after Phase I is done consistently find themselves underprepared when the Phase II preliminary injunction motion arrives.<\/p>\n\n\n\n

The Manufacturing Patents Problem<\/strong><\/h3>\n\n\n\n

A structurally underappreciated category in Phase II litigation is manufacturing process patents. These patents cover how a biologic is made \u2014 not what it is \u2014 and they present unique evidentiary challenges. Manufacturing processes for complex biologics involve dozens of variables: cell culture conditions, purification sequences, fill-finish parameters. Reference product sponsors have patented many of these variables, and proving non-infringement often requires the biosimilar applicant to share its own manufacturing details with the court.<\/p>\n\n\n\n

This creates a tension between the applicant’s interest in maintaining trade secret protection and its need to prove non-infringement through detailed process disclosure. Protective orders in BPCIA cases routinely include “attorney’s eyes only” provisions, but manufacturing personnel who must review and attest to non-infringement arguments face significant personal exposure if the court’s protective order is later challenged.<\/p>\n\n\n\n

DrugPatentWatch’s patent monitoring capabilities are particularly useful here. By tracking prosecution history for manufacturing-process patents and correlating them with aBLA filing dates, applicants can identify which process patents have broad enough claims to pose genuine infringement risk versus those whose claims are so narrow \u2014 based on prosecution-history estoppel \u2014 that they can be quickly dismissed. This front-end analysis saves substantial litigation expense later.<\/p>\n\n\n\n

Denosumab: A 2024\u20132025 Case Study in Multi-Defendant BPCIA Litigation<\/strong><\/h3>\n\n\n\n

The denosumab biosimilar litigation of 2024 and 2025 offers a current illustration of how complex multi-applicant BPCIA cases unfold. Amgen faced biosimilar challenges from Accord Biopharma, Celltrion, and Fresenius Kabi simultaneously for its Prolia\/Xgeva reference product (denosumab).<\/p>\n\n\n\n

Amgen filed a motion to consolidate the pending BPCIA litigations in New Jersey federal court in November 2024. [28] Biosimilar challengers opposed consolidation, preferring to maintain separate cases where each defendant’s specific aBLA and manufacturing process could be evaluated independently. The procedural skirmishing over venue and consolidation \u2014 before any substantive patent question was even addressed \u2014 consumed months of court time and substantial legal resources on all sides.<\/p>\n\n\n\n

By January 2025, Celltrion had entered a Consent Judgment and Injunction, agreeing to be enjoined from marketing its denosumab biosimilar pending further proceedings. [28] Fresenius Kabi and Accord proceeded on independent tracks. This fragmentation \u2014 where each biosimilar applicant pursuing the same reference product navigates the dance independently \u2014 creates opportunities for applicants to monitor each other’s proceedings. A patent invalidated in one BPCIA case provides prior art and legal precedent that other applicants can exploit.<\/p>\n\n\n\n

\n\n\n\n

Part VIII: Litigation Strategy for Reference Product Sponsors<\/strong><\/h2>\n\n\n\n

Patent Portfolio Architecture: Building Before the aBLA<\/strong><\/h3>\n\n\n\n

The most effective BPCIA litigation strategies for reference product sponsors are built years before the first biosimilar aBLA is filed. Patent portfolio architecture \u2014 the deliberate construction of a layered, overlapping patent estate covering the reference biologic’s composition, formulation, manufacturing, and methods of use \u2014 is the foundation of every durable defense.<\/p>\n\n\n\n

The Humira playbook is the canonical model, but it is not the only one. Merck pursued a similar strategy for Keytruda (pembrolizumab), seeking 129 patents including claims on sterile packaging. [20] The strategy works because the BPCIA creates no cap on patent assertions, and biosimilar developers must address every listed patent before they can launch without risk.<\/p>\n\n\n\n

But portfolio depth alone is insufficient. What matters is portfolio quality \u2014 specifically, at least one composition-of-matter patent or other foundational claim that is genuinely infringed by any biosimilar of the reference product and difficult to design around. Secondary patents on formulations and manufacturing may slow competitors, but a biosimilar applicant who can design around the secondary portfolio and invalidate the tertiary patents will eventually reach market. The core patent has to hold.<\/p>\n\n\n\n

The Royalty-Bearing Settlement as Competitive Management<\/strong><\/h3>\n\n\n\n

AbbVie’s settlement structure with adalimumab biosimilar manufacturers \u2014 delayed entry to 2023 plus royalties on future U.S. sales \u2014 represents a template that reference product sponsors in other therapeutic categories have studied carefully. The logic is that a negotiated competitive environment is preferable to an unpredictable litigation outcome.<\/p>\n\n\n\n

Royalty-bearing settlements also allow the RPS to maintain revenue from the reference product market even as biosimilars enter, because royalties effectively share the economics of the market rather than concede them entirely. From an antitrust perspective, these settlements occupy a gray area \u2014 the Federal Trade Commission has historically scrutinized pharmaceutical settlement agreements, and the line between a legitimate settlement and a “pay-for-delay” arrangement is not always clear.<\/p>\n\n\n\n

Reference product sponsors should have antitrust counsel evaluate any proposed settlement structure before execution. The risk of a subsequent FTC enforcement action or private antitrust litigation by payers and pharmacy benefit managers \u2014 who may have standing to sue for harms caused by delayed biosimilar entry \u2014 is real and documented.<\/p>\n\n\n\n

Formulation and Device Patents: The Second-Generation Moat<\/strong><\/h3>\n\n\n\n

AbbVie’s migration of Humira patients to a citrate-free, high-concentration formulation before biosimilar entry is a textbook example of a product-hopping strategy layered on top of patent portfolio depth. By the time biosimilars launched, a significant portion of the addressable market had already transitioned to a product formulation that biosimilar developers had not designed to match. [16]<\/p>\n\n\n\n

Autoinjector device patents present a related opportunity. Reference biologics that are delivered through proprietary autoinjector systems \u2014 where the device is covered by separate patents from the drug formulation \u2014 create an additional layer of complexity for biosimilar developers. A biosimilar might achieve full FDA approval as a biosimilar to the reference drug, but if it cannot be delivered in the same device and the reference device is patented, interchangeability designation becomes complicated.<\/p>\n\n\n\n

Reference product sponsors should evaluate device patents not just as a secondary IP moat but as a tool for complicating interchangeability \u2014 because an interchangeable biosimilar can be substituted at the pharmacy level without prescriber intervention, dramatically accelerating market penetration. Preventing interchangeability designation by maintaining device differentiators is one of the more effective long-term market protection strategies available under the current BPCIA framework.<\/p>\n\n\n\n

\n\n\n\n

Part IX: Litigation Strategy for Biosimilar Applicants<\/strong><\/h2>\n\n\n\n

The Integrated Pre-Filing Analysis<\/strong><\/h3>\n\n\n\n

Biosimilar applicants who win at the BPCIA game start their legal analysis years before the aBLA is filed. The most effective teams conduct an integrated freedom-to-operate (FTO) analysis that maps every patent in the reference product’s portfolio against the proposed biosimilar’s manufacturing process, formulation, and intended indications.<\/p>\n\n\n\n

Tools like DrugPatentWatch allow applicants to monitor the RPS’s patent prosecution activity in real time \u2014 tracking new applications, continuation filings, and allowance notices. [20] This live monitoring is not just defensive. It enables applicants to identify patents within their nine-month PGR window and file PGR petitions immediately, before those patents can become part of a consolidated thicket that would require IPR \u2014 with its narrower challenge grounds \u2014 to attack.<\/p>\n\n\n\n

The FTO analysis also informs aBLA design. Where possible, biosimilar applicants should engineer manufacturing processes that clearly diverge from patented RPS processes, reducing Phase II manufacturing patent exposure before the aBLA is even filed. This design-around work happens at the intersection of process chemistry and IP strategy, and it requires collaboration between R&D, regulatory, and legal teams that many smaller biosimilar developers fail to achieve.<\/p>\n\n\n\n

The Notice of Commercial Marketing: Timing as Strategy<\/strong><\/h3>\n\n\n\n

Post-Sandoz v. Amgen<\/em>, biosimilar applicants can send the 180-day notice of commercial marketing while the aBLA is under FDA review. This collapses what was previously a six-month post-approval waiting period into a period that runs concurrently with the FDA review cycle. For a biosimilar applicant who anticipates an 18-month FDA review, sending the notice immediately after aBLA acceptance means the 180-day clock expires before FDA approval \u2014 and the applicant can launch the day the approval issues, rather than waiting six more months.<\/p>\n\n\n\n

This is not a trivial timing optimization. Six months of first-mover exclusivity in a large market can represent hundreds of millions of dollars in revenue. Applicants who understand the post-Sandoz<\/em> notice timing advantage consistently arrive at market faster than those who treat the 180-day clock as a post-approval administrative formality.<\/p>\n\n\n\n

The IPR-and-Dance Pincer: Execution Details<\/strong><\/h3>\n\n\n\n

Running IPR petitions in parallel with the patent dance requires careful coordination to avoid legal pitfalls. The most important is the estoppel rule: an IPR petitioner who obtains a final written decision at PTAB is estopped from asserting in district court any invalidity ground that was raised or reasonably could have been raised during the IPR. [27]<\/p>\n\n\n\n

This means the IPR strategy must be coordinated with the dance’s claim chart positions. An invalidity argument that a biosimilar applicant intends to preserve for district court litigation should not be raised in an IPR petition. Conversely, IPR should be used aggressively for invalidity grounds that are strong but unlikely to succeed in district court due to the higher burden of proof.<\/p>\n\n\n\n

The pincer strategy has a timing consideration: IPR petitions must be filed within one year of the applicant being served with a complaint alleging infringement of the patent. [22] If the Phase I litigation involves patents that the applicant also wants to challenge at PTAB, the IPR petition must be filed within one year of Phase I suit being served. Missing that window permanently closes the IPR option for those patents.<\/p>\n\n\n\n

Managing the Interchangeability Designation<\/strong><\/h3>\n\n\n\n

As of July 2025, 25 first-to-market biosimilars had been designated as interchangeable by the FDA. [3] Interchangeability is commercially significant because it allows pharmacists to substitute the biosimilar for the reference product without prescriber intervention \u2014 the same automatic substitution that generics enjoy at the pharmacy counter.<\/p>\n\n\n\n

Pursuing interchangeability designation requires additional clinical data demonstrating that patients can switch between the reference product and the biosimilar without additional safety or efficacy concerns. This investment pays off commercially: interchangeable biosimilars gain market share faster because the substitution happens automatically at the point of dispensing rather than requiring active prescriber choice.<\/p>\n\n\n\n

However, reference product sponsors who hold device patents can complicate interchangeability by ensuring that the reference product’s delivery mechanism is patented in ways that prevent biosimilar manufacturers from using identical devices \u2014 which may be required for automatic substitution. Biosimilar applicants pursuing interchangeability should assess device patent exposure as part of their initial FTO analysis, not as an afterthought during FDA review.<\/p>\n\n\n\n

\n\n\n\n

Part X: The Inflation Reduction Act and the New Competitive Calculus<\/strong><\/h2>\n\n\n\n

IRA Price Negotiation and Its Interaction with Patent Protection<\/strong><\/h3>\n\n\n\n

The Inflation Reduction Act (IRA) introduced Medicare drug price negotiation for high-expenditure drugs, creating a new variable in the biosimilar competitive equation. Stelara (ustekinumab) was selected for IRA negotiation \u2014 and then, months after the negotiated price was announced, multiple biosimilar versions launched at prices more than 80% below Stelara’s brand list price. [3] As of July 2025, nine biosimilar products were on the market for Stelara at prices as much as 90% below the original list price. [3]<\/p>\n\n\n\n

This sequence raises a policy question that the pharmaceutical industry has not fully resolved: if IRA negotiation locks in a negotiated price before biosimilar competition begins, does it preempt the larger savings that competition would have delivered? The Association for Accessible Medicines argues yes \u2014 and points to the Stelara case as evidence that market competition can outperform government price negotiation. [3]<\/p>\n\n\n\n

For biosimilar applicants, the IRA creates a strategic consideration: if a reference product is or is likely to become an IRA negotiation target, the negotiated price becomes a price floor for biosimilar competition. A biosimilar priced significantly below the IRA-negotiated brand price creates payer value; one priced only modestly below may struggle to gain formulary placement. Reference product sponsors facing IRA selection may also find that the negotiated price reduces the perceived value of their patent portfolio \u2014 a product at IRA-mandated prices may not be worth the litigation cost to protect.<\/p>\n\n\n\n

The Biosimilar Void: A Market Failure in Formation<\/strong><\/h3>\n\n\n\n

The Association for Accessible Medicines identified a structural problem in its 2025 savings report: 90% of the 118 biologics expected to lose patent exclusivity over the next decade have no biosimilar in development. [3] This “biosimilar void” represents a potential $234 billion opportunity that is not being pursued \u2014 because the economics of BPCIA litigation, the difficulty of interchangeability designation, and payer formulary barriers have made biosimilar development unattractive for many molecules.<\/p>\n\n\n\n

The void matters for litigation strategy because it implies that reference product sponsors for many biologics may face no biosimilar challenge at all \u2014 not because of their patent portfolios, but because no company finds the economics attractive enough to engage. For molecules in this category, the extensive patent-thicket investments of the past decade may prove unnecessary. The more interesting strategic question for those reference product sponsors is whether their resources are better deployed into next-generation products that extend the revenue franchise beyond the patent cliff, rather than into additional layers of BPCIA-adjacent litigation.<\/p>\n\n\n\n

\n\n\n\n

Part XI: Using Patent Intelligence Tools in the Dance<\/strong><\/h2>\n\n\n\n

The Intelligence Advantage in BPCIA Litigation<\/strong><\/h3>\n\n\n\n

The patent dance generates an enormous amount of structured information: patent lists, claim charts, aBLA docket dates, notice of commercial marketing filings, PTAB petition dockets, and district court complaint schedules. Most of this information is publicly available in some form, but synthesizing it into actionable competitive intelligence requires dedicated monitoring infrastructure that many pharmaceutical companies lack.<\/p>\n\n\n\n

DrugPatentWatch provides this infrastructure for both sides of the dance. Reference product sponsors can use it to monitor when competitor aBLA filings trigger the start of the dance clock, assess which of their patents have been challenged at PTAB, and track settlement activity in comparable therapeutic categories. Biosimilar applicants use it to map patent thicket density, identify IPR filing windows, and benchmark their litigation timeline against comparable BPCIA cases. [20]<\/p>\n\n\n\n

The intelligence advantage in BPCIA litigation is not about knowing the law better than the other side. Both sides typically have excellent patent counsel. The advantage comes from knowing the landscape faster and more comprehensively \u2014 identifying an upcoming PGR window on a key secondary patent, or spotting a prosecution history disclaimer that narrows a blocking patent’s claims before the 3B claim charts are due. These are the marginal advantages that determine whether a biosimilar reaches market two years earlier or two years later.<\/p>\n\n\n\n

Monitoring Competitor aBLA Filings as an Early Warning System<\/strong><\/h3>\n\n\n\n

One underutilized application of patent intelligence tools is monitoring competitor aBLA filings for the same reference product. When multiple biosimilar applicants are pursuing the same reference biologic, their respective BPCIA proceedings create a shared information environment. A patent that is successfully challenged in one applicant’s IPR proceeding becomes weaker for every other applicant who faces the same patent.<\/p>\n\n\n\n

Biosimilar applicants who monitor parallel aBLA filings can coordinate legal strategy \u2014 not in ways that raise antitrust concerns, but in the sense of timing their own IPR petitions to benefit from prior art developed in a competitor’s proceeding, or timing their Phase I patent selection to account for patents that a competitor has already demonstrated are vulnerable.<\/p>\n\n\n\n

For reference product sponsors, monitoring competitor aBLA filings is equally critical. Knowing that three applicants are pursuing biosimilars for the same reference product changes the settlement calculus: a settlement with one applicant that allows a 2026 launch may be irrelevant if a second applicant achieves a court ruling invalidating the blocking patent in 2025.<\/p>\n\n\n\n

\n\n\n\n

Part XII: The International Dimension<\/strong><\/h2>\n\n\n\n

Why U.S. Biosimilar Entry Lags Europe<\/strong><\/h3>\n\n\n\n

The disparity between U.S. and European biosimilar market development is stark and documented. For Humira, biosimilar competition began in Europe years before the U.S. market. For Stelara, European biosimilar entry preceded U.S. entry. This disparity is not primarily a regulatory difference \u2014 the FDA’s biosimilar approval pathway is comparable in rigor to the European Medicines Agency’s. It is a patent law and litigation architecture difference.<\/p>\n\n\n\n

Europe does not have an equivalent to the BPCIA patent dance. Patent disputes in European biosimilar markets are handled through the individual national patent laws of EU member states, without the structured pre-litigation exchange. The absence of the dance’s complex procedural framework means European biosimilar developers face a different risk profile \u2014 less procedural delay before market entry, but also less structured information about what patents will be asserted.<\/p>\n\n\n\n

For U.S. biosimilar applicants, European launch timing data on comparable products provides useful benchmarking for what U.S. launch dates would look like absent BPCIA litigation complexity. When a reference product achieves biosimilar competition in Europe two years before comparable products reach the U.S. market, that gap is largely attributable to patent thickets and dance mechanics \u2014 not regulatory science.<\/p>\n\n\n\n

Global Patent Filing Strategy and Its U.S. Implications<\/strong><\/h3>\n\n\n\n

Reference product sponsors who file patents globally must manage the interaction between their U.S. portfolio strategy and international patent prosecution. Prosecution history developed in European Patent Office proceedings \u2014 including arguments made to overcome prior art, claim amendments, and examiner interviews \u2014 can be used in U.S. district court litigation as extrinsic evidence bearing on claim scope.<\/p>\n\n\n\n

A reference product sponsor who made limiting arguments before the EPO to secure European patent claims may find those same arguments narrowing the scope of the corresponding U.S. patent in BPCIA litigation. Biosimilar applicants with sophisticated international prosecution monitoring capabilities regularly locate these cross-jurisdictional prosecution history disclaimers \u2014 and use them to limit a blocking patent’s claims before the Phase II fight begins.<\/p>\n\n\n\n

\n\n\n\n

Part XIII: Practical Checklist for Biosimilar Applicants<\/strong><\/h2>\n\n\n\n

Pre-aBLA Filing (24\u201336 Months Before Submission)<\/strong><\/h3>\n\n\n\n

The foundational work for BPCIA litigation happens long before the aBLA is filed. Applicants who wait until aBLA submission to begin their patent analysis are already behind. The critical pre-filing activities include a comprehensive FTO analysis covering all patents in the reference product’s portfolio, identification of patents within their PGR filing window, and an assessment of which manufacturing process parameters in the aBLA could be engineered to avoid the most commercially significant process patents.<\/p>\n\n\n\n

This phase also includes establishing a patent monitoring protocol. Using services like DrugPatentWatch, applicants should set alerts for new patent applications from the RPS that name the reference biologic, continuation filings from existing patent families, and PTAB proceedings filed by other parties against the same patents. The competitive intelligence gathered during this phase shapes every subsequent strategic decision.<\/p>\n\n\n\n

aBLA Submission Through FDA Acceptance (Weeks 1\u20134 Post-Submission)<\/strong><\/h3>\n\n\n\n

Immediately upon FDA acceptance of the aBLA, the dance clock starts. The applicant must decide within 20 days whether to share the aBLA with the RPS. This decision should have been made at least six months earlier \u2014 not in a 20-day window under time pressure. Applicants who have not pre-decided their dance participation strategy by the time FDA acceptance arrives are operating reactively.<\/p>\n\n\n\n

If the decision is to participate in the dance, the 3B claim charts must be prepared immediately. These are the most consequential documents the applicant will produce in the entire BPCIA process \u2014 they define the applicant’s invalidity and non-infringement positions before litigation begins, and they will be tested in every subsequent proceeding. They require the applicant’s best technical and legal thinking, not expedited drafting.<\/p>\n\n\n\n

The 180-day notice of commercial marketing should also be sent immediately upon FDA acceptance if the applicant intends to maximize the timing benefit. Waiting until post-approval sacrifices the pre-approval overlap that collapses the notice period into the FDA review window.<\/p>\n\n\n\n

Phase I Litigation Through Trial<\/strong><\/h3>\n\n\n\n

Phase I patent selection \u2014 choosing which patents from the RPS’s 3A list to litigate in the first wave \u2014 is the applicant’s single most important tactical decision. The selection should maximize the probability of invalidity findings while minimizing the risk of preliminary injunction. Composition-of-matter patents with clean prosecution histories and broad claims should be avoided in Phase I if possible; formulation patents with extensive prior art and narrow prosecution-history-limited claims are better candidates.<\/p>\n\n\n\n

Coordinate IPR filings against non-selected Phase I patents during this period. Target the patents most likely to survive Phase I and reappear as Phase II threats. A PTAB institution decision finding that these patents have a reasonable likelihood of invalidity \u2014 even before a final written decision \u2014 provides settlement leverage and shapes Phase II posture.<\/p>\n\n\n\n

The Settlement Decision Point<\/strong><\/h3>\n\n\n\n

In approximately two-thirds of BPCIA litigations, settlement terminates the dispute before a final court ruling. [20] For biosimilar applicants, the settlement decision requires honest assessment of litigation risk against the cost of a delayed launch date. A settlement that allows launch in 18 months, with no royalties, may be worth more than a 40% probability of winning full invalidity findings in 36 months with legal costs of $50 million.<\/p>\n\n\n\n

Reference product sponsors, conversely, should resist the temptation to settle too early on terms that undervalue their portfolio. A preliminary injunction in hand provides negotiating leverage that disappears if it is dissolved or if a Phase I patent is found invalid. Settlement timing should track the litigation’s substantive posture \u2014 strong after a favorable court ruling, less favorable after an adverse PTAB institution decision.<\/p>\n\n\n\n

\n\n\n\n

Part XIV: The Litigation Outlook for 2025\u20132030<\/strong><\/h2>\n\n\n\n

The Stelara Wave and What Comes Next<\/strong><\/h3>\n\n\n\n

The adalimumab biosimilar wave of 2023 and the ustekinumab (Stelara) wave of 2024\u20132025 represent the two largest biosimilar patent cliffs in U.S. pharmaceutical history to date. As of July 2025, nine biosimilar products were competing for the ustekinumab market at prices up to 90% below Stelara’s brand list price. [3] The price compression in both markets has been dramatic \u2014 adalimumab biosimilars reached ASP discounts averaging 52% for the trastuzumab market and Hadlima’s WAC at 85\u201386% below Humira’s. [45]<\/p>\n\n\n\n

The next wave includes major biologics approaching patent cliffs in immunology and oncology. Dupixent (dupilumab), Keytruda (pembrolizumab), and Opdivo (nivolumab) are among the highest-revenue biologics whose patent estates will face biosimilar challenge in the late 2020s. Each will generate BPCIA litigation activity that tests the frameworks and precedents established in the Humira and Stelara generations.<\/p>\n\n\n\n

For Keytruda specifically, Merck’s 129-patent filing strategy mirrors AbbVie’s Humira approach. Whether Merck can execute the same settlement-with-delay outcome depends on the quality of its core composition-of-matter patents and its willingness to accept royalty-bearing entry agreements from biosimilar challengers. The oncology biosimilar market behaves differently from the immunology market \u2014 oncology biosimilars have achieved 80\u201390% market share within three years of launch for bevacizumab and trastuzumab \u2014 suggesting that the market conditions favor competitive entry once patents are resolved. [45]<\/p>\n\n\n\n

The Role of the IRA in Reshaping BPCIA Strategy<\/strong><\/h3>\n\n\n\n

IRA price negotiation targets will increasingly overlap with biosimilar development timelines. When CMS selects a drug for negotiation, it establishes a negotiated maximum price. If a biosimilar subsequently launches at a price significantly below the negotiated brand price, the negotiated price becomes economically irrelevant \u2014 but the process of negotiation may have delayed formulary decisions by payers who were waiting for the outcome.<\/p>\n\n\n\n

This creates a new timing consideration for biosimilar applicants: if the reference product is likely to be selected for IRA negotiation, applicants who can achieve market entry before or concurrent with the negotiation process avoid the market uncertainty that negotiation creates. A biosimilar on the market before CMS’s negotiated price is announced is already positioned in payer formularies; one that enters afterward faces the challenge of displacing a reference product that payers have already repriced.<\/p>\n\n\n\n

Artificial Intelligence and Patent Analytics in BPCIA Strategy<\/strong><\/h3>\n\n\n\n

The analytical complexity of BPCIA litigation \u2014 mapping patent portfolios against aBLA manufacturing processes, modeling litigation timelines across multiple patents and defendants, identifying prosecution history disclaimers across hundreds of continuation patents \u2014 is exactly the type of multi-variable, document-intensive problem where AI-assisted patent analytics is beginning to change practice.<\/p>\n\n\n\n

Tools that can automatically map claim language against manufacturing process parameters, flag prosecution history amendments that limit claim scope, and track PTAB proceeding outcomes across comparable patent families are increasingly available. For biosimilar applicants preparing 3B claim charts across a 60-patent 3A list, AI-assisted claim mapping can reduce the time and cost of that analysis substantially. For reference product sponsors monitoring competitive aBLA filings, automated alerts linked to patent prosecution status provide early warning of challenge timing.<\/p>\n\n\n\n

The competitive advantage from these tools comes from deploying them earlier in the development cycle \u2014 not as a litigation support function, but as a strategic input into aBLA design, manufacturing process engineering, and patent portfolio construction. Firms that integrate patent analytics into R&D decision-making from the earliest stages of biosimilar development will consistently outperform those that treat patent analysis as a pre-litigation exercise.<\/p>\n\n\n\n

\n\n\n\n

Conclusion: The Dance Is a Long Game<\/strong><\/h2>\n\n\n\n

The patent dance is not a discrete event. It is the opening movement of a multi-year strategic campaign that began when the reference biologic was first developed and will not end until the last relevant patent expires or is invalidated. Every step \u2014 the 3A list, the 3B claim charts, the Phase I patent selection, the PTAB petitions, the Phase II preliminary injunction fight \u2014 is connected to every other step through a web of strategic consequence.<\/p>\n\n\n\n

Companies that win BPCIA litigation do not win because they are better litigators in the conventional sense. They win because they started their analysis earlier, they built their patent portfolios or their invalidity arguments more carefully, and they understood the interaction between the dance’s procedural mechanics and the commercial outcomes those mechanics produce.<\/p>\n\n\n\n

The financial stakes will only grow. With the global biosimilar market projected to reach $151 billion by 2033 and 90% of biologics losing exclusivity over the next decade having no biosimilar competitor in development, the companies that master BPCIA strategy will define which molecules achieve competitive entry \u2014 and which remain perpetual brand monopolies. [2][3]<\/p>\n\n\n\n

That is not a legal question. It is a business strategy question with legal execution requirements. The patent dance is the arena where that strategy gets tested.<\/p>\n\n\n\n

\n\n\n\n

Key Takeaways<\/strong><\/h2>\n\n\n\n
    \n
  • The patent dance is legally optional for biosimilar applicants after Sandoz v. Amgen<\/em> (2017), but opting out eliminates the structural benefit of controlling Phase I patent selection \u2014 making it the wrong choice for applicants facing large patent thickets.<\/li>\n\n\n\n
  • AbbVie’s Humira defense \u2014 105+ patents, royalty-bearing settlements, and product-hopping to a citrate-free formulation \u2014 is the template that every reference product sponsor studies and that every biosimilar applicant must plan for in immunology and beyond.<\/li>\n\n\n\n
  • PTAB remains a powerful parallel challenge forum for biosimilar applicants despite 2025 procedural reforms. Bio\/pharma patents are being instituted at near-100% rates even as overall IPR institution rates fell below 45%. Post-Grant Review petitions, filed within nine months of patent grant, should now be standard practice for newly issued secondary patents.<\/li>\n\n\n\n
  • Approximately 67% of BPCIA litigations resolve through settlement rather than full adjudication. The settlement decision requires disciplined NPV analysis against litigation risk \u2014 not a reflexive preference for trial or capitulation.<\/li>\n\n\n\n
  • The 180-day notice of commercial marketing should be sent immediately upon aBLA acceptance, not after FDA approval. The post-Sandoz<\/em> timing rule allows applicants to compress the pre-launch waiting period by running the 180-day clock concurrently with FDA review.<\/li>\n\n\n\n
  • Patent intelligence platforms like DrugPatentWatch provide real-time monitoring of reference product patent prosecution, PTAB petition activity, and competitive aBLA filings \u2014 intelligence that should inform aBLA design and manufacturing process engineering years before litigation begins.<\/li>\n\n\n\n
  • The IRA price negotiation framework creates new timing dynamics: biosimilar applicants who can achieve market entry before or concurrent with CMS negotiation avoid the formulary uncertainty that negotiation creates for payers.<\/li>\n\n\n\n
  • The “biosimilar void” \u2014 90% of biologics losing exclusivity over the next decade with no biosimilar in development \u2014 signals that BPCIA litigation complexity has made development economics unattractive for many molecules. This represents a $234 billion missed opportunity for the healthcare system. [3]<\/li>\n<\/ul>\n\n\n\n
    \n\n\n\n

    Frequently Asked Questions<\/strong><\/h2>\n\n\n\n

    Q1: Can a biosimilar applicant opt back into the patent dance after initially opting out?<\/strong><\/h3>\n\n\n\n

    No. Once a biosimilar applicant notifies the RPS that it will not provide the aBLA and manufacturing information under 42 U.S.C. \u00a7 262(l)(2)(A), the structured information exchange ceases. The applicant cannot later reinstate the dance’s procedural framework. The practical consequence is that the RPS may then file suit asserting its full patent portfolio without the sorting mechanism the dance provides. Some applicants have attempted partial information sharing after initially opting out, but courts have been inconsistent in determining whether such voluntary disclosures revive any of the dance’s procedural protections. If there is any possibility of wanting the dance’s benefits, the safer choice is to participate from the start.<\/p>\n\n\n\n

    Q2: What happens when two biosimilar applicants are pursuing the same reference product simultaneously \u2014 does a patent finding in one case bind the other?<\/strong><\/h3>\n\n\n\n

    Patent validity findings are not technically binding on other parties through issue preclusion (collateral estoppel) unless the other party was in privity with the losing party in the prior case. In practice, however, a district court or PTAB finding that a specific patent is invalid creates persuasive precedent that subsequent courts and PTAB panels take seriously. More importantly, a final written PTAB decision invalidating a patent claim has a statutory effect under 35 U.S.C. \u00a7 318 that cancels those claims \u2014 making the patent legally unenforceable against any party, including other biosimilar applicants who were not parties to the proceeding. This is why well-coordinated PTAB strategy by any single biosimilar applicant can benefit the entire field of competitors pursuing the same reference product.<\/p>\n\n\n\n

    Q3: How should a reference product sponsor prioritize which patents to include on the 3A list when the portfolio runs to dozens or hundreds of patents?<\/strong><\/h3>\n\n\n\n

    The 3A list strategy involves competing considerations. Including every patent maximizes leverage and ensures that no patent is left outside the Phase II universe, but it also exposes every patent to applicant scrutiny in the 3B exchange and to potential PTAB challenges. A targeted list that emphasizes patents with strong claim scope, clean prosecution histories, and clear infringement reads on the anticipated biosimilar manufacturing process is generally preferable to a comprehensive dump. The RPS should also consider which patents it genuinely intends to litigate: a 3A list that includes 60 patents but where the RPS realistically expects to litigate only eight signals weakness and invites applicant skepticism. Demonstrating a credible willingness to litigate across a significant portion of the listed portfolio is what creates settlement pressure.<\/p>\n\n\n\n

    Q4: What is the interaction between the BPCIA patent dance and antitrust law \u2014 specifically, can a reference product sponsor be sued for using the dance to delay competition?<\/strong><\/h3>\n\n\n\n

    This is one of the most actively litigated and theoretically unsettled areas in biopharmaceutical antitrust law. A series of antitrust complaints against AbbVie for its Humira patent litigation strategy \u2014 including both the patent thicket construction and the settlement agreements that delayed U.S. entry \u2014 were dismissed in Chicago federal court, with the Seventh Circuit upholding the dismissal. The courts have been reluctant to treat legitimate patent assertion, even in large volume, as per se anticompetitive. However, two specific conduct categories carry elevated antitrust risk: Walker Process fraud (asserting patents known to have been obtained through inequitable conduct before the USPTO) and sham litigation (filing suits with no reasonable expectation of winning, for the purpose of imposing litigation costs on competitors). Reference product sponsors whose patent portfolios include large numbers of patents that were knowingly obvious over the prior art \u2014 and who asserted them primarily to impose delay rather than out of genuine infringement belief \u2014 face non-trivial Walker Process exposure as the litigation record develops.<\/p>\n\n\n\n

    Q5: With the PTAB institutional rate for overall IPRs dropping below 45% in 2025, how should biosimilar applicants adjust their patent challenge strategy?<\/strong><\/h3>\n\n\n\n

    The declining overall IPR institution rate masks a divergence: bio\/pharma petitions are being instituted at near-100% rates under the new discretionary denial framework, even as other technology sectors face dramatically reduced access. [26] So the direct answer for biosimilar applicants is that IPR remains highly accessible for pharmaceutical patent challenges. The strategic adjustments should focus on two areas: first, filing Post-Grant Review petitions within the nine-month window for any newly issued RPS secondary patent, because PGR’s broader challenge grounds make it more powerful than IPR and the window is short; second, evaluating ex parte reexamination as a supplement for double-patenting challenges, which do not require standing and face no time bar. For applicants in markets where the PREVAIL Act’s potential passage is a planning risk, building alternative challenge arguments that would succeed at the clear-and-convincing standard \u2014 not just preponderance \u2014 provides litigation resilience if the statutory framework shifts.<\/p>\n\n\n\n

    \n\n\n\n

    Citations<\/strong><\/h2>\n\n\n\n
      \n
    1. Association for Accessible Medicines. (2025). 2025 U.S. Generic & Biosimilar Medicines Savings Report<\/em>. https:\/\/accessiblemeds.org\/resources\/reports\/2025-savings-report\/<\/li>\n\n\n\n
    2. Grand View Research. (2025). Biosimilars Market Size And Share | Industry Report, 2033<\/em>. https:\/\/www.grandviewresearch.com\/industry-analysis\/biosimilars-market<\/li>\n\n\n\n
    3. Mulcahy, A. W., Buttorff, C., Finegold, K., Hernandez, A., Lovejoy, S., Shetty, K., & Whaley, C. (2022). Projected US savings from biosimilars, 2021\u20132025. The American Journal of Managed Care, 28<\/em>(7), 329\u2013335. https:\/\/www.ajmc.com\/view\/projected-us-savings-from-biosimilars-2021-2025<\/li>\n\n\n\n
    4. IQVIA Institute. (2023). Biosimilars in the United States 2023\u20132027<\/em>. IQVIA. https:\/\/www.iqvia.com\/insights\/the-iqvia-institute\/reports-and-publications\/reports\/biosimilars-in-the-united-states-2023-2027<\/li>\n\n\n\n
    5. Biologics Price Competition and Innovation Act of 2009, Pub. L. No. 111-148, 42 U.S.C. \u00a7 262 (2010).<\/li>\n\n\n\n
    6. Goodwin Procter LLP. (2024, December 9). Guide to Biosimilars Litigation and Regulation in the U.S., 2024\u20132025 Edition<\/em>. Thomson Reuters. https:\/\/www.bigmoleculewatch.com\/2024\/12\/09\/now-available-updated-goodwins-guide-to-biosimilars-litigation-and-regulation-in-the-u-s-2024-2025\/<\/li>\n\n\n\n
    7. Sandoz Inc. v. Amgen Inc.<\/em>, 137 S. Ct. 1664 (2017).<\/li>\n\n\n\n
    8. Feldman, R., Frondorf, E., Cordey, A. K., & Wang, C. (2022). Biological patent thickets and delayed access to biosimilars, an American problem. PLOS ONE<\/em>. https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC9439849\/<\/li>\n\n\n\n
    9. Center for Biosimilars. (2021, July 24). The inner workings of the BPCIA patent dance. https:\/\/www.centerforbiosimilars.com\/view\/the-inner-workings-of-the-bpcia-patent-dance<\/li>\n\n\n\n
    10. DrugPatentWatch. (2025, July 21). Biosimilar patent dance: Leveraging PTAB challenges for strategic advantage<\/em>. https:\/\/www.drugpatentwatch.com\/blog\/biosimilar-patent-dance-leveraging-ptab-challenges-for-strategic-advantage\/<\/li>\n\n\n\n
    11. Center for Biosimilars. (2024, August 20). Patent dance insights: A Q&A on reducing legal battles in the biosimilar landscape. https:\/\/www.centerforbiosimilars.com\/view\/patent-dance-insights-a-q-a-on-reducing-legal-battles-in-the-biosimilar-landscape<\/li>\n\n\n\n
    12. Finnegan, Henderson, Farabow, Garrett & Dunner LLP. (2020). Following the patent dance three years after Sandoz. https:\/\/www.finnegan.com\/en\/insights\/articles\/following-the-patent-dance-three-years-after-sandoz.html<\/li>\n\n\n\n
    13. BioSpace. (2024, December 18). Lessons from Humira on how to tackle unjust extensions of drug monopolies with policy. https:\/\/www.biospace.com\/policy\/opinion-lessons-from-humira-on-how-to-tackle-unjust-extensions-of-drug-monopolies-with-policy<\/li>\n\n\n\n
    14. DrugPatentWatch. (2025, November 4). The thicket maze: A strategic guide to navigating and dismantling drug patent fortresses<\/em>. https:\/\/www.drugpatentwatch.com\/blog\/the-thicket-maze-a-strategic-guide-to-navigating-and-dismantling-drug-patent-fortresses\/<\/li>\n\n\n\n
    15. DrugPatentWatch. (2025, December 4). The biosimilar launch window: A predictive framework for navigating patents, payers, and litigation<\/em>. https:\/\/www.drugpatentwatch.com\/blog\/the-biosimilar-launch-window-a-predictive-framework-for-navigating-patents-payers-and-litigation\/<\/li>\n\n\n\n
    16. I-MAK. (2024). Biologics, biosimilars, and patents<\/em>. https:\/\/www.i-mak.org\/wp-content\/uploads\/2024\/05\/Biologics-Biosimilars-Guide_IMAK.pdf<\/li>\n\n\n\n
    17. DrugPatentWatch. (2025, July 24). Exploring biosimilars as a drug patent strategy<\/em>. https:\/\/www.drugpatentwatch.com\/blog\/exploring-biosimilars-as-a-drug-patent-strategy-navigating-the-complexities-of-biologic-innovation-and-market-access\/<\/li>\n\n\n\n
    18. Association for Accessible Medicines. (2025, June 4). Patent settlements are necessary to help combat patent thickets. https:\/\/accessiblemeds.org\/resources\/blog\/patent-settlements-are-necessary-to-help-combat-patent-thickets\/<\/li>\n\n\n\n
    19. Petrie-Flom Center, Harvard Law School. (2021). AbbVie wins first round in Humira antitrust lawsuit. https:\/\/petrieflom.law.harvard.edu\/2021\/01\/06\/abbvie-humira-antitrust-patent-thicket\/<\/li>\n\n\n\n
    20. DrugPatentWatch. (2026, January 8). Mastering the dance: A strategic guide to the BPCIA biosimilar patent timeline and litigation<\/em>. https:\/\/www.drugpatentwatch.com\/blog\/mastering-the-dance-a-strategic-guide-to-the-bpcia-biosimilar-patent-timeline-and-litigation\/<\/li>\n\n\n\n
    21. Baker Botts LLP. (2015, March). Inter partes review (IPR): An alternative pathway for biosimilars. http:\/\/www.bakerbotts.com\/insights\/publications\/2015\/03\/ptab-trials-report2<\/li>\n\n\n\n
    22. DrugPatentWatch. (2025, July 21). Biosimilar patent dance: Leveraging PTAB challenges for strategic advantage<\/em>. https:\/\/www.drugpatentwatch.com\/blog\/biosimilar-patent-dance-leveraging-ptab-challenges-for-strategic-advantage\/<\/li>\n\n\n\n
    23. Biosimilars Law Bulletin. (2026, January 27). PTAB reforms shift the battleground: Why ex parte reexaminations are gaining ground as IPRs fade. https:\/\/www.biosimilarsip.com\/2026\/01\/27\/ptab-reforms-shift-the-battleground-why-ex-parte-reexaminations-are-gaining-ground-as-iprs-fade\/<\/li>\n\n\n\n
    24. DrugPatentWatch. (2026, March 24). The patent trial and appeal board: The definitive analyst’s guide to IPR strategy<\/em>. https:\/\/www.drugpatentwatch.com\/blog\/understanding-the-patent-trial-and-appeal-board-ptab-a-comprehensive-overview\/<\/li>\n\n\n\n
    25. DrugPatentWatch. (2026, April). Drug patent challenges: The complete strategic playbook for IP teams and portfolio managers<\/em>. https:\/\/www.drugpatentwatch.com\/blog\/when-science-meets-law-the-art-and-strategy-of-challenging-drug-patents\/<\/li>\n\n\n\n
    26. Goodwin Procter LLP. Big Molecule Watch. BPCIA litigations tracker (updated March 9, 2026). https:\/\/www.bigmoleculewatch.com\/bpcia-patent-litigations\/<\/li>\n\n\n\n
    27. Center for Biosimilars. (2020). The uncertainty of BPCIA litigation strategies and the ‘patent dance.’ https:\/\/www.centerforbiosimilars.com\/view\/the-uncertainty-of-bpcia-litigation-strategies-and-the-patent-dance<\/li>\n\n\n\n
    28. Center for Biosimilars. (2024, November 12). Breaking down biosimilar barriers: The patent system. https:\/\/www.centerforbiosimilars.com\/view\/breaking-down-biosimilar-barriers-the-patent-system<\/li>\n\n\n\n
    29. AJMC. (2025, Q1). Biosimilar market share: Growth and price trends in Q1 2025. https:\/\/www.ajmc.com\/view\/biosimilar-market-share-growth-and-price-trends-in-q1-2025<\/li>\n\n\n\n
    30. STAT News. (2025, September 1). The biosimilar market looks unsustainable right now, and that’s a problem. https:\/\/www.statnews.com\/sponsor\/2025\/09\/01\/biosimilar-market-looks-unsustainable-right-now-and-thats-a-problem\/<\/li>\n\n\n\n
    31. American Journal of Managed Care. (2023). Humira: The first $20 billion drug. https:\/\/www.ajmc.com\/view\/humira-the-first-20-billion-drug<\/li>\n<\/ol>\n","protected":false},"excerpt":{"rendered":"

      Biologic drugs represent 2% of all U.S. prescriptions but consume 37% of net drug spending. [1] That arithmetic explains everything […]<\/p>\n","protected":false},"author":1,"featured_media":38790,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_lmt_disableupdate":"","_lmt_disable":"","site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"default","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","ast-disable-related-posts":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"footnotes":""},"categories":[10],"tags":[],"class_list":["post-38785","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-insights"],"modified_by":"DrugPatentWatch","_links":{"self":[{"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/posts\/38785","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/comments?post=38785"}],"version-history":[{"count":1,"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/posts\/38785\/revisions"}],"predecessor-version":[{"id":38791,"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/posts\/38785\/revisions\/38791"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/media\/38790"}],"wp:attachment":[{"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/media?parent=38785"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/categories?post=38785"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/tags?post=38785"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}